Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema

American Journal of Ophthalmology

Volumn 164, Issue , 2016, Pages 57-68

  Bressler, Susan B ^a   Glassman, Adam R ^b   Almukhtar, Talat ^b   Bressler, Neil M ^a   Ferris, Frederick L ^c   Googe, Joseph M ^d   Gupta, Shailesh K ^e   Jampol, Lee M ^f   Melia, Michele ^b   Wells, John A ^g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

^d Southeastern Retina Associates   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g Palmetto Retina Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CATARACT; CENTRAL RETINAL THICKNESS; CENTRAL SUBFIELD THICKNESS; CLINICAL OUTCOME; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFECT; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; MACULAR VOLUME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE CENTRAL SUBFIELD THICKNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETIC RETINOPATHY; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MULTIMODALITY CANCER THERAPY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85017052430     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2015.12.025     Document Type: Article

References (5)

1. Elman, M.J., Bressler, N.M., Qin, H., et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118:4 (2011), 609–614.
2. Elman, M.J., Ayala, A., Bressler, N.M., et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122:2 (2015), 375–381.
3. Diabetic Retinopathy Clinical Research Network, Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:6 (2010), 1064–1077.e35.
4. Brown, D.M., Nguyen, Q.D., Marcus, D.M., et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:10 (2013), 2013–2022.
5. Schmidt-Erfurth, U., Lang, G.E., Holz, F.G., et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE Extension Study. Ophthalmology 121:5 (2014), 1045–1053.